Breakthrough Medicines for treatment of Cancer and Inflammatory diseases

TARGET TO HIT

HIT TO LEAD

LEAD OPTIMIZATION

CANDIDATE/IND

PHASE I

RORγt Inhibitor
Candidate Selection
BRD (BD1)
Lead optimization
Cytokine X
Hit-to-lead
GRP78
Hit-to-lead
RORγt Agonist
Hit-to-lead
NSD1/2/3
Screening
Upcoming
Screening